Search results
Jun 20, 2024 · Developed by Tasuku Honjo, Graduate School of Medicine, Kyoto University. The construct was electoroporated into TT2 ES cells derived from (C57BL/6 x CBA)F1. The mutant mice were backcrossed to C57BL/6N. Strain description: AID (Aicda, activation-induced cytidine deaminase) knockout mice.
- RBRC00897
- B6.Cg-Aicda (N10)/HonRbrc
- Mus musculus
- Targeted Mutation Congenic
Jun 24, 2024 · While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30% of patients. We interview Japanese researchers who are trying to overcome this challenge. ...
Jun 19, 2024 · Nobel medicine Award winning Immunologist Tasuku Honjo proudly accepts his award and says that he wants to continue further cancer research for others.
- 2 min
Jun 21, 2024 · In 1984, with Dr Uchiyama, the Nobel Laureate Prof Tasuku Honjo led the study to clone the previously unknown IL-2 receptor gene, which led to the successful cloning of the CD25 (Il2ra) gene (Nikaido et al, 1984).
Jul 10, 2024 · TAIPEI, Nov. 27, 2021 /PRNewswire/ -- Following the inspiring opening speech, "Future Perspective of Cancer Immunotherapy," delivered by Nobel Prize and Tang Prize laureate Prof. Tasuku Honjo at the 14 th Asia Pacific Federation of Pharmacologist Conference (APFP) on November 26, the 2020 Tang Prize Laureate's Lecture for Biopharmaceutical Science, co-organized by the Tang Prize Foundation and ...
Jun 21, 2024 · 05.26 2021 / 【New Series】 “KBIC innovator interviews” ~The first featured innovator is TASUKU HONJO, M.D., Ph.D. , President of FBRI. 05.26 2021 / 【Event/Seminar】3rd KBIC Global Webinar ~ German Ecosystem and Collaboration Opportunities ~
Jun 20, 2024 · Developed by Dr. Tasuku Honjo, Kyoto University: Strain description: The PD1 (programmed cell death 1) gene is an immunoinhibitory receptor that belongs to the CD28 family, and plays a role in the negative control of proliferation, differentiation and class switching of B cells.
